Median overall survival and 18-month overall survival data continue to show improvements over historical controls1
- One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline
- Next steps :
Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022
Primary GBM: randomized, controlled evaluation in the frontline setting expected to initiate in Q4 2022 as part of INSIGhT adaptive platform trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.